ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge
ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...
J.P. Morgan Sticks to Its Buy Rating for Resmed (RMD)
In a report released on January 31, David Low from J.P. Morgan maintained a Buy rating on Resmed (RMD – Research Report), with a price target ...
The New York Times2d
The Best Portable Monitors
We’ve updated this guide with new portable monitors we saw at CES 2025 that we plan to test soon. We’ve included more details in the What to look forward to section. January 2025 Rolling up to ...
This gentle form of exercise reduces your risk of sleep apnea by 10%, study says
Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...
ResMed: Snoozers Can Be Winners
ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...
ResMed Inc. stock falls Friday, underperforms market
Shares of ResMed Inc. shed 8.33% to $236.18 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.50% to 6,040.53 and Dow Jones ...